invivo mab rat anti mouse cd4 (Bio X Cell)
Structured Review

Invivo Mab Rat Anti Mouse Cd4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 778 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rat+anti+mouse+cd4+mab/InVivoMAb+anti-mouse+CD4/pmc12208319-28-0-8
Average 97 stars, based on 778 article reviews
Images
1) Product Images from "Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade"
Article Title: Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade
Journal: Cell Reports Medicine
doi: 10.1016/j.xcrm.2025.102141
Figure Legend Snippet: Anti-CTLA-4 antibodies remodel tumor vasculature and increase TA-HEVs through Fc-dependent mechanisms (A) Treatment schedule. i.p., intraperitoneal; IF, immunofluorescence; control, isotype control antibodies. (B) Mean tumor growth ( n = 9 mice per group; data pooled from two independent experiments). (C) Gating strategy for CD45 − CD31 high endothelial cells and MECA-79 + TA-HECs. (D and E) Frequencies of CD45 − CD31 high endothelial cells and TA-HECs. Each symbol represents an individual mouse ( n = 9, two independent experiments). (F and G) Mean fluorescence intensity (MFI) of MECA-79 and CD62P in TA-HECs, quantified by flow cytometry. Each symbol represents an individual mouse ( n = 9, two independent experiments). (H and I) Immunofluorescence of MCA prog tumor (day 12) following treatment with 9D9 mouse anti-CTLA-4 antibody. Selected markers are presented. Scale bars: 100 μm. (J) Schematics of the two distinct 9D9 anti-CTLA-4 antibodies used in the study. (K and L) Mean tumor growth and tumor weights in individual mice ( n = 15 mice per group; data pooled from three independent experiments). (M–O) Frequencies of CD45 − CD31 high endothelial cells, TA-HECs, and MECA-79 + CD62P + TA-HECs. Each symbol represents an individual mouse ( n = 15, three independent experiments). Representative dot plots of TA-HECs are shown (N). (P and Q) MFI of MECA-79 and CD62P in TA-HECs, quantified by flow cytometry. Each symbol represents an individual mouse ( n = 15, three independent experiments). (R) Numbers of tumor-infiltrating CD4 + and CD8 + T cells. Each symbol represents an individual mouse ( n = 15, three independent experiments). Data are shown as mean ± SEM. All p values were determined by one-way ANOVA with Tukey’s multiple comparison test, except for (B) and (K) for which p values were determined by two-way ANOVA with Dunnett’s multiple comparison test. See also and .
Techniques Used: Immunofluorescence, Control, Fluorescence, Flow Cytometry, Comparison
Figure Legend Snippet: Tbet + ICOS + Th1-like CD4 + T cells correlate with TA-HEVs during anti-CTLA-4 therapy (A–C) Frequency of FOXP3 + Tregs and numbers of FOXP3 − Tconv and FOXP3 + Tregs in tumors following indicated treatments. Representative dot plots of FOXP3 + Tregs are shown (A). Each symbol represents an individual mouse ( n = 15, three independent experiments). (D) Ratio of Tconv to Treg cell numbers in tumors following indicated treatments. Each symbol represents an individual mouse ( n = 15, three independent experiments). (E) Mean fluorescence intensity (MFI) of selected markers in Tregs, quantified by flow cytometry. Each symbol represents an individual mouse (FOXP3, Tbet, PD-1, and ICOS, n = 15, three independent experiments; CTLA-4 and CD39, n = 7–8, two independent experiments). (F) Frequency of CTLA-4 + CD25 + Tregs in tumors following indicated treatments. Representative dot plots are shown. Each symbol represents an individual mouse ( n = 7–8, two independent experiments). (G) MFI of selected markers in Tconv, quantified by flow cytometry. Each symbol represents an individual mouse ( n = 15, three independent experiments). (H and I) Frequency and number of Tbet + ICOS + Th1-like CD4 + T cells in tumors following indicated treatments. Representative dot plots are shown (H). Each symbol represents an individual mouse ( n = 15, three independent experiments). (J) Frequency of Ki67 high cells in Tbet + ICOS + Th1-like CD4 + T cells in tumors following indicated treatments. Each symbol represents an individual mouse ( n = 15, three independent experiments). (K and L) Correlation analysis between the number of tumor-infiltrating Tbet + ICOS + Th1-like CD4 + T cells and the frequencies of CD45 − CD31 high endothelial cells or MECA-79 + TA-HECs. Each symbol represents an individual mouse, and simple linear regression lines are shown in red (data pooled from six independent experiments; n = 30 mice treated with 9D9 or 9H10 anti-CTLA-4 antibodies). p values and Pearson’s r were determined by Pearson correlation test. (M) Histograms showing expression of PD-1 in Tbet − ICOS − (DN), Tbet − ICOS + (SP), and Tbet + ICOS + (DP) FOXP3 − Tconv from MCA prog tumors (day 12) following treatment with 9D9 anti-CTLA-4 antibody, quantified by flow cytometry. MFI of PD-1 is quantified in indicated subsets. Each symbol represents an individual mouse ( n = 15, three independent experiments). (N) Frequency of IFNγ + cells in CD44 + PD-1 + CD4 + T cells stimulated ex vivo , following indicated treatments. Each symbol represents an individual mouse ( n = 9, two independent experiments). Data are shown as mean ± SEM. All p values were determined by one-way ANOVA with Tukey’s multiple comparison test except for graphs in (E)–(G) and (N) for which p values were determined by unpaired two-tailed Student’s t test. See also .
Techniques Used: Fluorescence, Flow Cytometry, Expressing, Ex Vivo, Comparison, Two Tailed Test
Figure Legend Snippet: CD4 + T cells are important for the increase of TA-HEVs during anti-CTLA-4 therapy (A) Treatment schedule. i.p., intraperitoneal; control, isotype control antibodies. (B and C) Frequencies of CD45 − CD31 high endothelial cells and MECA-79 + TA-HECs. Each symbol represents an individual mouse ( n = 8–9, two independent experiments). (D and E) Number of tumor-infiltrating CD8 + T cells and frequency of Ki67 high cells in tumor-infiltrating CD8 + T cells. Each symbol represents an individual mouse ( n = 8–9, two independent experiments). (F and G) Frequency of PD-1 high cells in tumor-infiltrating CD44 + CD8 + T cells following indicated treatments, and mean fluorescence intensity (MFI) of PD-1 in the same subset, quantified by flow cytometry. Representative dot plots are shown (F). Each symbol represents an individual mouse ( n = 8–9, two independent experiments). (H and I) Frequency and number of GzmB + cells in tumor-infiltrating CD44 + PD-1 + CD8 + T cells. Representative dot plots are shown (H). Each symbol represents an individual mouse ( n = 8–9, two independent experiments). (J) Treatment schedule. i.p., intraperitoneal; control, isotype control antibodies. (K–Q) Frequencies of CD45 − CD31 high endothelial cells, TA-HECs, MECA-79 + CD62P + TA-HECs, number of TA-HECs, and MFI of MECA-79 and CD62P in TA-HECs, following indicated treatments, quantified by flow cytometry. Each symbol represents an individual mouse ( n = 10, two independent experiments). (R and S) Numbers of tumor-infiltrating CD4 + and CD8 + T cells, and frequency of Ki67 high cells in tumor-infiltrating CD8 + T cells. Each symbol represents an individual mouse ( n = 10, two independent experiments). Data are shown as mean ± SEM. All p values were determined by one-way ANOVA with Tukey’s multiple comparison test except for graphs in (K)–(S) for which p values were determined by unpaired two-tailed Student’s t test. See also and .
Techniques Used: Control, Fluorescence, Flow Cytometry, Comparison, Two Tailed Test
Figure Legend Snippet: Fc-optimized ipilimumab combined with anti-PD-1 increases TA-HEVs and melanoma tumor control in humanized mice (A) Treatment schedule. i.p., intraperitoneal; control, isotype control antibodies. (B–D) Mean tumor growth, Kaplan-Meier survival curves, and individual tumor growth. Data were obtained from two independent experiments (control, n = 12 mice; anti-PD-1, n = 10 mice; ipilimumab-GAALIE, n = 12 mice; ipilimumab-GAALIE + anti-PD-1, n = 12 mice). (E) Treatment schedule. i.p., intraperitoneal; IF, immunofluorescence; control, isotype control antibodies. (F–H) Immunofluorescence of B16F10 tumor (day 15) following treatment with ipilimumab-GAALIE + anti-PD-1 antibodies. Selected markers are presented. Inset in (G) and (H) show higher magnifications of boxed areas. Scale bars: 500 μm (F), 50 μm (G left, H left, and H right), 20 μm (G right). (I and J) Frequencies of TA-HECs and MECA-79 + CD62P + TA-HECs. Each symbol represents an individual mouse ( n = 9–10, two independent experiments). (K and L) Frequency and numbers of Tbet + ICOS + Th1-like CD4 + T cells in tumors. Representative dot plots are shown (K). Each symbol represents an individual mouse ( n = 9–10, two independent experiments). (M) Number of tumor-infiltrating CD8 + T cells. Each symbol represents an individual mouse ( n = 9–10, two independent experiments). Data are shown as mean ± SEM. All p values were determined by unpaired two-tailed Student’s t test except for (B) for which p values were determined by two-way ANOVA with Dunnett’s multiple comparison test, and for graph in (C) for which p values were determined by log rank test.
Techniques Used: Control, Immunofluorescence, Two Tailed Test, Comparison
Related Articles
Control:Article Title: Frontline Science: CD40 signaling restricts RNA virus replication in Mϕs, leading to rapid innate immune control of acute virus infection Article Snippet: In vivo blockage of CD40 signaling was performed by administering 250 μg of inhibitory hamster anti-mouse CD154 Ab (Clone MR-1, BioXCell) or polyclonal Armenian hamster IgG (BioXCell). .. Depletion of T-cells was performed by administering 200 μg of rat anti-mouse CD8mAb (Clone 2.43, BioXCell) in combination with |


